SG11201406987UA - Glucokinase activator compositions for the treatment of diabetes - Google Patents
Glucokinase activator compositions for the treatment of diabetesInfo
- Publication number
- SG11201406987UA SG11201406987UA SG11201406987UA SG11201406987UA SG11201406987UA SG 11201406987U A SG11201406987U A SG 11201406987UA SG 11201406987U A SG11201406987U A SG 11201406987UA SG 11201406987U A SG11201406987U A SG 11201406987UA SG 11201406987U A SG11201406987U A SG 11201406987UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lllll
- diabetes
- llll
- pct
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 229940124828 glucokinase activator Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 abstract 2
- 108010011459 Exenatide Proteins 0.000 abstract 2
- 241000219492 Quercus Species 0.000 abstract 2
- 229960001519 exenatide Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- HPGJSAAUJGAMLV-QAQDUYKDSA-N C1C[C@@H](OCCC)CC[C@@H]1N(C(=O)NC=1SC(SCC(O)=O)=CN=1)C1CCCCC1 Chemical compound C1C[C@@H](OCCC)CC[C@@H]1N(C(=O)NC=1SC(SCC(O)=O)=CN=1)C1CCCCC1 HPGJSAAUJGAMLV-QAQDUYKDSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 238000000540 analysis of variance Methods 0.000 abstract 1
- 229940127003 anti-diabetic drug Drugs 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940000425 combination drug Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 abstract 1
- 229960004034 sitagliptin Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648110P | 2012-05-17 | 2012-05-17 | |
| PCT/US2013/041076 WO2013173417A2 (en) | 2012-05-17 | 2013-05-15 | Glucokinase activator compositions for the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406987UA true SG11201406987UA (en) | 2014-12-30 |
Family
ID=48576527
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406987UA SG11201406987UA (en) | 2012-05-17 | 2013-05-15 | Glucokinase activator compositions for the treatment of diabetes |
| SG10201609644UA SG10201609644UA (en) | 2012-05-17 | 2013-05-15 | Glucokinase activator compositions for the treatment of diabetes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201609644UA SG10201609644UA (en) | 2012-05-17 | 2013-05-15 | Glucokinase activator compositions for the treatment of diabetes |
Country Status (16)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2576524B1 (en) | 2010-05-26 | 2017-10-25 | vTv Therapeutics LLC | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| HK1202458A1 (en) * | 2012-05-17 | 2015-10-02 | Vtv治疗有限责任公司 | Glucokinase activator compositions for the treatment of diabetes |
| KR102408480B1 (ko) | 2018-05-30 | 2022-06-10 | 이삼구 | 당뇨질환의 치료용 조성물 |
| CN110548149B (zh) * | 2018-05-31 | 2022-01-14 | 华领医药技术（上海）有限公司 | 含葡萄糖激酶激活剂和α-葡萄糖苷酶抑制剂的药物组合及其制备方法和用途 |
| CA3093025A1 (en) * | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US11872221B2 (en) | 2020-01-31 | 2024-01-16 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator |
| WO2021151251A1 (en) * | 2020-01-31 | 2021-08-05 | Hua Medicine (Shanghai) Ltd. | Treating treatment-resistant diabetes with glucokinase activator |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| WO2021243645A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| AU2020451966A1 (en) * | 2020-06-04 | 2023-01-19 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with hepatic impairment |
| MX2022015524A (es) * | 2020-06-08 | 2023-03-22 | Vtv Therapeutics Llc | Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. |
| JP2023530786A (ja) * | 2020-06-08 | 2023-07-19 | ブイティーブイ・セラピューティクス・エルエルシー | ｛２－［３－シクロヘキシル－３－（ｔｒａｎｓ－４－プロポキシ－シクロヘキシル）－ウレイド］－チアゾール－５－イルスルファニル｝－酢酸の塩または共結晶およびその使用 |
| CN115350268B (zh) * | 2022-08-24 | 2025-02-11 | 深圳青澜生物技术有限公司 | 一种用于治疗糖尿病的制剂、微针及其制备工艺 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT323195B (de) | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | Verfahren zur herstellung neuer salze von biguaniden |
| FR2243684B1 (enrdf_load_stackoverflow) | 1973-09-19 | 1977-01-28 | Semb | |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| SI1133312T1 (sl) * | 1999-06-21 | 2008-02-29 | Lilly Co Eli | Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina |
| US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| PL215132B1 (pl) | 2002-06-27 | 2013-10-31 | Novo Nordisk As | Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca |
| WO2004076420A1 (ja) | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
| KR20060052650A (ko) | 2003-07-14 | 2006-05-19 | 소니 가부시끼 가이샤 | 정보제공방법 |
| AU2003269484A1 (en) | 2003-09-11 | 2005-03-29 | Biocon Limited | Salt of atorvastatin with metformin |
| ES2399052T3 (es) * | 2004-01-06 | 2013-03-25 | Novo Nordisk A/S | Heteroaril-ureas y su uso como activadores de glucocinasa |
| CN1910166B (zh) * | 2004-01-06 | 2012-01-04 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
| WO2005123132A2 (en) * | 2004-06-17 | 2005-12-29 | Novo Nordisk A/S | Use of liver-selective glucokinase activators |
| US20060246141A1 (en) | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
| US20100028439A1 (en) | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| US7999114B2 (en) | 2005-07-08 | 2011-08-16 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
| CN101258137A (zh) * | 2005-07-08 | 2008-09-03 | 诺沃-诺迪斯克有限公司 | 双环烷基脲葡糖激酶活化剂 |
| EP1904466A1 (en) | 2005-07-08 | 2008-04-02 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| BRPI0612996A2 (pt) | 2005-07-14 | 2010-12-14 | Novo Nordisk As | ativadores de urÉia glucocinase |
| EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2008084043A1 (en) | 2007-01-09 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
| TWI445707B (zh) | 2008-05-16 | 2014-07-21 | Takeda California Inc | 葡萄糖激酶活化劑 |
| US8680230B2 (en) | 2008-07-22 | 2014-03-25 | Kureha Corporation | Production process of poly(arylene sulfide) whose content of terminal halogen group has been reduced |
| WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
| DK2419097T3 (da) | 2009-04-16 | 2013-10-28 | Taisho Pharmaceutical Co Ltd | Farmaceutisk sammensætning omfattende (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol og metformin og anvendelser deraf i behandling af diabetes |
| WO2011025270A2 (ko) | 2009-08-25 | 2011-03-03 | 한올바이오파마주식회사 | 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학조성물 및 그를 포함하는 복합제제 |
| EP2576524B1 (en) * | 2010-05-26 | 2017-10-25 | vTv Therapeutics LLC | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| EP2392575A1 (en) * | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
| HK1202458A1 (en) | 2012-05-17 | 2015-10-02 | Vtv治疗有限责任公司 | Glucokinase activator compositions for the treatment of diabetes |
| ES2794018T3 (es) | 2013-03-04 | 2020-11-17 | Vtv Therapeutics Llc | Composiciones sólidas que comprenden un activador de la glucoquinasa y métodos para crearlas y usarlas |
| KR20150123838A (ko) | 2013-03-04 | 2015-11-04 | 브이티브이 테라퓨틱스 엘엘씨 | 안정한 글루코키나제 활성화제 조성물 |
-
2013
- 2013-05-15 HK HK15103235.2A patent/HK1202458A1/xx unknown
- 2013-05-15 CA CA2872021A patent/CA2872021C/en active Active
- 2013-05-15 AU AU2013262895A patent/AU2013262895A1/en not_active Abandoned
- 2013-05-15 CN CN202410499223.0A patent/CN118453592A/zh active Pending
- 2013-05-15 BR BR112014028622A patent/BR112014028622A2/pt not_active Application Discontinuation
- 2013-05-15 EP EP13726933.8A patent/EP2849776B1/en active Active
- 2013-05-15 SG SG11201406987UA patent/SG11201406987UA/en unknown
- 2013-05-15 KR KR1020147035545A patent/KR20150013838A/ko not_active Ceased
- 2013-05-15 MX MX2014013105A patent/MX360304B/es active IP Right Grant
- 2013-05-15 EA EA201492109A patent/EA201492109A1/ru unknown
- 2013-05-15 SG SG10201609644UA patent/SG10201609644UA/en unknown
- 2013-05-15 JP JP2015512779A patent/JP6234443B2/ja active Active
- 2013-05-15 WO PCT/US2013/041076 patent/WO2013173417A2/en active Application Filing
- 2013-05-15 KR KR1020217006420A patent/KR102371364B1/ko active Active
- 2013-05-15 CN CN201380024802.XA patent/CN104349790A/zh active Pending
- 2013-05-15 IN IN9554DEN2014 patent/IN2014DN09554A/en unknown
- 2013-05-15 ES ES13726933T patent/ES2878001T3/es active Active
- 2013-11-05 US US14/071,976 patent/US10004782B2/en active Active
-
2014
- 2014-11-03 IL IL235484A patent/IL235484A0/en unknown
-
2017
- 2017-06-07 AU AU2017203835A patent/AU2017203835B2/en active Active
-
2018
- 2018-05-18 US US15/983,249 patent/US10588943B2/en active Active
-
2020
- 2020-01-16 US US16/744,956 patent/US10980861B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2872021C (en) | 2022-08-16 |
| CN118453592A (zh) | 2024-08-09 |
| WO2013173417A3 (en) | 2014-02-20 |
| IL235484A0 (en) | 2014-12-31 |
| KR102371364B1 (ko) | 2022-03-07 |
| US20200138909A1 (en) | 2020-05-07 |
| IN2014DN09554A (enrdf_load_stackoverflow) | 2015-07-17 |
| MX2014013105A (es) | 2015-04-08 |
| CA2872021A1 (en) | 2013-11-21 |
| MX360304B (es) | 2018-10-29 |
| AU2017203835A1 (en) | 2017-06-22 |
| HK1202458A1 (en) | 2015-10-02 |
| JP6234443B2 (ja) | 2017-11-22 |
| US10588943B2 (en) | 2020-03-17 |
| BR112014028622A2 (pt) | 2017-06-27 |
| US20140066372A1 (en) | 2014-03-06 |
| JP2015517525A (ja) | 2015-06-22 |
| AU2013262895A1 (en) | 2014-11-13 |
| US10980861B2 (en) | 2021-04-20 |
| KR20150013838A (ko) | 2015-02-05 |
| US20180311314A1 (en) | 2018-11-01 |
| WO2013173417A2 (en) | 2013-11-21 |
| EP2849776B1 (en) | 2021-04-21 |
| EP2849776A2 (en) | 2015-03-25 |
| SG10201609644UA (en) | 2017-01-27 |
| US10004782B2 (en) | 2018-06-26 |
| KR20210027547A (ko) | 2021-03-10 |
| CN104349790A (zh) | 2015-02-11 |
| EA201492109A1 (ru) | 2015-07-30 |
| AU2017203835B2 (en) | 2018-11-22 |
| ES2878001T3 (es) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201406987UA (en) | Glucokinase activator compositions for the treatment of diabetes | |
| SG11201408261UA (en) | Syringe | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201407961WA (en) | Risperidone or paliperidone implant formulation | |
| SG11201811580SA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201407971QA (en) | Paliperidone implant formulation | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201407919WA (en) | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] | |
| SG11201407364QA (en) | Occlusion detection | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201805941WA (en) | Tgfbeta 2 antibodies | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |